Proton Partners Intl - Partnership with Northumbria Healthcare NHS Trust London Stock Exchange
RNS Number : 7528C
Proton Partners International Ltd.
19 June 2019

19 June 2019                       



Proton Partners International's Rutherford Cancer Centre North East and Northumbria Healthcare today announced a landmark partnership that will see NHS cancer patients treated at the Rutherford Centre in Bomarsund.

The partnership applies to chemotherapy patients and is designed to help the trust ensure treatments for cancer patients are not delayed. Initially, the Rutherford Cancer Centre will treat breast cancer patients with chemotherapy - an estimated 120-150 patients a year.

The Rutherford Cancer Centre North East offers a range of advanced cancer treatments including chemotherapy, immunotherapy, radiotherapy and proton beam therapy as well as diagnostic services.

Chris Land, Centre Manager at the Rutherford Cancer Centre North East, said: "We are delighted to have formalised this partnership with Northumbria Healthcare that will ensure patients who need chemotherapy in the region do not face delays. The North East has some of the highest incidences of cancer in the UK and partnerships such as this are important in ensuring better patient outcomes in the region."

"The efforts of both our organisations are centred around patients having access to the most advanced treatments and precision radiotherapy."

Sir James Mackey, chief executive of Northumbria Healthcare, said: "We are very pleased to announce this partnership which will provide tremendous benefits for cancer patients across the region and is part of our on-going commitment to provide outstanding care to everyone who needs it - complementing the services we already provide from Northumbria.

"No one wants to wait for treatment especially when they have been diagnosed with cancer - it can be an anxious time for patients and their loved ones. Working with the Rutherford Cancer Centre will ensure our patients get timely access and state of the art treatment."

Mike Moran, CEO of Proton Partners International, the company that operates the Rutherford Cancer Centres, said: "It is hugely encouraging to see the private and public sectors working collaboratively to improve outcomes for cancer patients in the North East. Earlier this year we struck a similar partnership with the Welsh Government to provide proton beam therapy services to adult Welsh NHS patients and it is evident that working together is beneficial to patients."

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

The directors of Proton Partners International Limited accept responsibility for this announcement.


Proton Partners International Limited



Michael Moran, Chief Executive Officer

Tel: +44 (0) 16 3381 0661





Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100


Colin Aaronson/ Jamie Barklem/ Niall McDonald






Media House International



Ramsay Smith

07788 414 856 or


Ibrahim Khalil

0207 710 0020 or




About the Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing advanced cancer care and creating a better future for cancer patients. The centres provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, immunotherapy, radiotherapy and proton beam therapy treatment.

The Rutherford Cancer Centres feature the most advanced technologies and Proton Partners International has formed a partnership with IBA (Ion Beam Applications), the world's leading provider of proton beam therapy solutions and Philips, a leader in health technology.

All centres offer proton beam therapy to medically-insured private patients, self-paying patients and NHS patients where the Rutherford is commissioned to provide these services.

For more information on the Rutherford Cancer Centres, please visit:

Follow the Rutherford Cancer Centres on twitter: @therutherford_c




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit